XLCARE PHARMACEUTICALS INC - NEW AWARD FOR LEVOTHYROXINE NA TABLETS WITH XLCARE PHARMACEUTICALS, INC. BASE YEAR ORDERING PERIOD IS JAN 27, 2025 THROUGH JAN 26, 2026 WITH FOUR ONE-YEAR OPTIONS
Key Details
Description
NEW AWARD FOR LEVOTHYROXINE NA TABLETS WITH XLCARE PHARMACEUTICALS, INC. BASE YEAR ORDERING PERIOD IS JAN 27, 2025 THROUGH JAN 26, 2026 WITH FOUR ONE-YEAR OPTIONS
Context & Analysis
On Nov 20, 2025, Department of Veterans Affairs to XLCARE PHARMACEUTICALS INC for new award for levothyroxine na tablets with xlcare pharmaceuticals, inc. base year ordering period is jan 27, 2025 through jan 26, 2026 with four one-year options. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 3 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.